Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis



Status:Completed
Conditions:High Blood Pressure (Hypertension), Gastrointestinal
Therapuetic Areas:Cardiology / Vascular Diseases, Gastroenterology
Healthy:No
Age Range:18 - 75
Updated:2/16/2018
Start Date:June 2015
End Date:October 2017

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo
controlled, double blind study. This study will enroll subjects with portal hypertension
(HVPG greater than or equal to 6 mm Hg) who also have a liver biopsy with cirrhosis (Ishak
stage 5 or 6), presumably due to NASH, excluding subjects with medium and large varices and
those with decompensated cirrhosis.

Subjects with portal hypertension and cirrhosis will be randomly assigned (1:1:1 ratio) to
receive 1 of 3 treatment assignments including placebo, GR MD 02 in a dose of 2 mg/kg lean
body mass, or GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over
a 52 week period for a total of 26 intravenous infusions. The primary endpoint analysis is
the baseline adjusted change in HVPG at 1 year (53 55 weeks) in subjects treated with placebo
as compared to subjects treated with GR MD 02 (2 mg/kg/week or 8 mg/kg/week).

An esophagogastroduodenoscopy (EGD) with evaluation for varices, HVPG, and liver biopsy will
be performed before the first infusion and after the final 26th dose of IMP. Additionally,
subjects will undergo a FibroScan (if available) prior to the first infusion, at Infusion
Visit 13, and 14 to 28 days following final 26th infusion, an MBT (if available) will be
performed at screening, at Infusion Visit 13, and 14 to 28 days after the final infusion, and
blood will be collected for assessment of biomarkers.

All subjects are to attend 2 postdose visits: the first will occur 14 to 28 days after the
final dose administration and a second will occur 14 days following the first postdose visit.

Subjects will be offered enrollment into a subsequent separate study, an open label extension
study, if there is adequate tolerability and no safety issues or signs of clinical
progression that would recommend discontinuation.

Subjects who do not enroll in the open label extension study will be contacted via telephone
every 6 months for 2 years and annually thereafter for a total of 4 years.


Inclusion Criteria:

1. Has a HVPG measurement ≥6 mm Hg.

2. Has a liver biopsy with cirrhosis (Ishak stage 5 or 6) presumably due to NASH. A liver
biopsy diagnosis of cirrhosis presumably due to NASH will include the following 3
categories:

- Cirrhosis with a definitive pathological diagnosis of NASH (presence of fat,
ballooning degeneration, and inflammation);

- Cirrhosis wherein the biopsy contains either fat (>5%) or ballooning hepatocytes
with no evidence of viral hepatitis or other liver disease; or

- Cirrhosis with no evidence of viral hepatitis or other liver disease in a subject
with at least a 5 year history of obesity (BMI ≥30) or at least a 5 year history
of diabetes mellitus (as defined by diagnosis by a physician and treatment with
at least 1 antidiabetic medication).

3. Is ≥18 years of age and ≤75 years of age at the time of screening.

4. Absence of hepatocellular carcinoma by valid imaging (liver ultrasound, triple phase
computed tomography of liver or magnetic resonance imaging of liver) within 6 months
prior to randomization. If there is not such test available, then it should be
performed as part of standard of care.

5. Is willing and able to provide written informed consent prior to the initiation of any
study specific procedures.

6. Is not pregnant and must have a negative serum pregnancy test result prior to
randomization.

7. If a fertile man or woman participating in heterosexual relations, agrees to use
effective means of contraception (ie, 2 effective methods of contraception, one of
which must be a physical barrier method).

• Effective forms of contraception include condom, hormonal methods (birth control
pills, injections or implants), diaphragm, cervical cap, or intrauterine device
throughout his/her participation in this study and for 90 days after discontinuation
of study treatment. Surgically sterile males and females are not required to use
contraception provided they have been considered surgically sterile for at least 6
months. Surgical sterility includes history of vasectomy, hysterectomy, bilateral
salpingo oophorectomy, or bilateral tubal ligation. Postmenopausal women who have been
amenorrheic for at least 2 years at the time of screening will be considered sterile.

8. If a lactating woman, agrees to discontinue nursing before the start of study
treatment and refrain from nursing until 90 days after the last dose of study
treatment.

9. If a man, agrees to refrain from sperm donation throughout the study period and for a
period of 90 days following the last dose of IMP. Female subjects may not begin a
cycle of ova donation or harvest throughout the study period and for a period of 90
days following the last dose of IMP.

10. Prior to randomization, any subject on statins, angiotensin converting enzyme
inhibitors, angiotensin II receptor blockers, or β 1 selective adrenergic receptor
inhibitors should have been on a stable dose for at least 2 months and all attempts
should be made to continue the subject on the same dose of the medication for the
duration of study participation.

Exclusion Criteria:

1. Has a history of hepatic decompensation including any episode of variceal bleeding,
ascites not controlled by medication, or overt hepatic encephalopathy (defined by the
clinical judgment of the principal investigator but shall include the presence of
lethargy, disorientation, inappropriate behavior, and the presence of asterixis).

2. Has a presence of medium or large varices or varices with red signs regardless of size
based on endoscopy.

- Small varices are defined by veins that occupy <25% of the distal one third of
the esophageal lumen when insufflated. Veins that completely flatten upon
insufflation of the esophagus are not conserved varices. Any varices larger than
that are medium (up to 50%) or large (>50%).

- Red signs include red wale markings (dilated venules oriented longitudinally on
the variceal surface), cherry red spots (small, red, spotty dilated venules
usually approximately 2 mm in diameter on the variceal surface) or hematocystic
spots (large, round, crimson red projection >3 mm that look like a blood blister
on the variceal surface).

3. Has had a prior transjugular porto systemic shunt procedure.

4. Has evidence of other forms of chronic liver disease including viral hepatitis B or C,
primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alpha 1
antitrypsin deficiency, alcoholic hepatitis, hemochromatosis, liver cancer, history of
biliary diversion, or autoimmune hepatitis.

5. Has any of the following laboratory values:

- Serum alanine aminotransferase levels >10 × the upper limits of normal

- Serum aspartate aminotransferase levels >10 × the upper limits of normal

- Platelet count <60 000/mm3

*. Serum albumin ≤2.8 g/dL

- International normalized ratio (INR) ≥1.7

- Direct bilirubin ≥2.0 mg/dL

- Alpha fetoprotein >200 ng/mL

6. Has a MELD score ≥15 or Child Turcotte Pugh Class B or C.

7. Has an estimated creatinine clearance of <50 mL/minute. Glomerular filtration rate
will be estimated using the Cockcroft-Gault equation (Cockcroft 1976):

- Males: CrCl (mL/min) = ([140 - age] × weight) / (SCr × 72)

- Females: CrCl (mL/min) = ([140 - age]) × weight) / (SCr × 72)] × 0.85

- Where CrCl is creatinine clearance, age is in years, weight is in kg, and SCr is
serum creatinine in mg/dL

8. Is unwilling or unable to safely undergo HVPG or liver biopsy.

9. Has known positivity for human immunodeficiency virus (HIV) infection or a positive
HIV test result at screening.

10. Has had major surgery within 8 weeks of randomization, significant traumatic injury
within 6 months, or anticipation of need for major surgical procedure during the
course of the study.

11. Has a history of a solid organ transplant requiring current immunosuppression therapy.

12. Has used nonselective β adrenergic inhibitors within 6 weeks prior to randomization.

13. Has planned or anticipated variceal ligation therapy during the study.

14. Has had weight reduction surgery within the past 3 years or plans to undergo weight
reduction surgery during the study.

15. Has current, significant alcohol consumption or a history of significant alcohol
consumption for a period of more than 3 consecutive months any time within 1 year
prior to screening.

• Significant alcohol consumption is defined as more than 20 grams per day in females
and more than 30 grams per day in males. On average, a standard drink in the United
States is considered to be 14 grams of alcohol, equivalent to 12 fluid ounces of
regular beer (5% alcohol), 5 fluid ounces of table wine (12% alcohol), or 1.5 fluid
ounces of 80 proof spirits (40% alcohol).

A score of ≥8 on the Alcohol Use Disorders Identification Test (AUDIT) (Babor 2000)
will result in exclusion.

16. Has a positive urine screen result for amphetamines, cocaine, or nonprescription
opiates (heroin, morphine) at screening.

17. Has clinically significant and uncontrolled cardiovascular disease (eg, uncontrolled
hypertension, myocardial infarction within 6 months prior to randomization, unstable
angina), New York Heart Association Grade II or greater congestive heart failure,
serious cardiac arrhythmia requiring devise/ablation or Grade II or greater peripheral
vascular disease within 12 months prior to randomization.

18. Has a history of clinically significant hematologic, renal, hepatic, pulmonary,
neurological, psychiatric, gastrointestinal, systemic inflammatory, metabolic or
endocrine disorder or any other condition that, in the opinion of the investigator,
renders the subject a poor candidate for inclusion into the study.

19. Has concurrent infection including diagnoses of fever of unknown origin at the time of
randomization.

20. Has a history of malignancy, except for the following: adequately treated
nonmetastatic basal cell skin cancer; any other type of skin cancer, except melanoma,
that has been adequately treated and has not recurred for at least 1 year prior to
enrollment; and adequately treated in situ cervical cancer that has not recurred for
at least 1 year prior to screening.

21. Participates in an investigational new drug study within 30 days prior to
randomization (including follow up visits) or at any time during the current study.

22. Has a clinically significant medical or psychiatric condition considered high risk for
participation in an investigational study.

23. Fails to give informed consent.

24. Has known allergies to the IMP or any of its excipients.

25. Has previously received GR-MD-02 within 6 months of randomization.

26. Is an employee or family member of the investigator or study center personnel.
We found this trial at
46
sites
San Diego, California 92103
Principal Investigator: Rohit Loomba, MD
Phone: 619-543-5584
?
mi
from
San Diego, CA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Michelle Lai, MD
Phone: 617-632-1068
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Giuseppe Morelli, MD
Phone: 352-273-9464
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Brian Borg, MD
Phone: 601-815-6127
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Mazen Noureddin, MD
Phone: 310-423-7704
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: David Bernstein, MD
Phone: 516-562-2082
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
Principal Investigator: Maria Hernandez, MD
Phone: 305-243-6968
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Andrew Scanga, MD
Phone: 615-936-1745
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Kuchikulla Reddy, MD
Phone: 215-349-8507
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Principal Investigator: Charles Landis, MD
Phone: 206-744-7063
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Hari Conjeevaram, MD
Phone: 734-232-4182
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Arlington, Texas 76012
Principal Investigator: Reem Ghalib, MD
Phone: 817-471-1070
?
mi
from
Arlington, TX
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
(404) 605-5000
Principal Investigator: Raymond Rubin, MD
Phone: 404-605-2905
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Kiran Bambha, MD
Phone: 303-724-1871
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
345 St Paul Pl
Baltimore, Maryland 21202
(410) 332-9000
Principal Investigator: Paul Thuluvath, MD
Phone: 410-576-5298
Mercy Medical Center "Mercy Medical Center" is a hospital located in Baltimore, Maryland. The landmark...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Dawn Torres, MD
Phone: 301-295-6127
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Don Rockey, MD
Phone: 843-876-8439
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Mary Rinella, MD
Phone: 312-694-0326
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44194
Principal Investigator: Pierre Gholam, MD
Phone: 216-844-3878
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Jacqueline O'Leary, MD
Phone: 817-424-1525
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Stuart Gordon, MD
Phone: 313-916-1962
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Manal Abdelmalek, MD
Phone: 919-668-6579
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Sam Houston, Texas 78234
?
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: John Vierling, MD
Phone: 832-355-8708
?
mi
from
Houston, TX
Click here to add this to my saved trials
340 W 10th St #6200
Indianapolis, Indiana 46202
(317) 274-3772
Principal Investigator: Naga Chalasani, MD
Phone: 317-278-9245
Indiana University School of Medicine With more than 2,000 students in 2013, the Indiana University...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Missouri 64128
Principal Investigator: Prashant Pandya, DO
Phone: 816-861-4700
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lakewood Ranch, Florida 34211
?
mi
from
Lakewood Ranch, FL
Click here to add this to my saved trials
Live Oak, Texas 78233
?
mi
from
Live Oak, TX
Click here to add this to my saved trials
5121 S Cottonwood St
Murray, Utah 84157
(801) 507-7000
Principal Investigator: Michael Charlton, MD
Phone: 801-507-9333
Intermountain Medical Center Intermountain Medical Center is one of the most technologically advanced and patient-friendly...
?
mi
from
Murray, UT
Click here to add this to my saved trials
1430 Tulane Ave Suite SL32
New Orleans, Louisiana 70112
(504) 588-5912
Principal Investigator: Luis Balart, MD
Phone: 504-988-3047
Tulane University Health Sciences Center One of the nation's most recognized centers for medical education,...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Julia Wattacheril, MD
Phone: 212-305-3839
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport News, Virginia 23602
Principal Investigator: Mitchell Shiffman, MD
Phone: 757-947-3191
?
mi
from
Newport News, VA
Click here to add this to my saved trials
Norfolk, Virginia 23502
Principal Investigator: Michael Ryan, MD
Phone: 757-961-1110
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Palmetto Bay, Florida
Principal Investigator: Miguel Rodriguez, MD
Phone: (786) 310-7477
?
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Dina Halegoua-De Marzio, MD
Phone: 215-955-8108
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Providence, Rhode Island 02905
Principal Investigator: Thomas Sepe, MD
Phone: 401-421-8800
?
mi
from
Providence, RI
Click here to add this to my saved trials
Richmond, Virginia 23226
Principal Investigator: Mitchell Shiffman, MD
Phone: 804-287-7666
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Richmond, Virginia 23249
Principal Investigator: Michael Fuchs, MD
Phone: 804-675-5584
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Arun Sanyal, MD
Phone: 804-828-5434
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
2315 Stockton Blvd.
Sacramento, California 95817
(916) 734-2011
Principal Investigator: Christopher Bowlus, MD
Phone: 916-734-2911
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Paul, Minnesota 55114
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
San Antonio, Texas 78215
Principal Investigator: Eric Lawitz, MD
Phone: 210-253-3426
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Kris Kowdley, MD
Phone: 206-215-2927
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida 33606
Principal Investigator: Nyingi Kemmer, MD
Phone: 813-844-5689
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Winston-salem, North Carolina 27103
?
mi
from
Winston-salem, NC
Click here to add this to my saved trials